What is the uterine cancer phase 3?
In stage 3 uterus cancer, this disease has spread behind the uterus and cervix, but not the pelvis. The uterine cancer stage is divided into 3A, 3B and 3C compressions based on how far the cancer has moved to the pelvic area. Once cancer is diagnosed, other tests including computed tomography, X -rays and blood analysis are used to determine the disease. Hysterectomy may also be required. Cancer staging is a decisive step because it determines the patient treatment and prognosis. There are four phases of this type of cancer. As soon as cancer expands behind the uterus, it will be phase 3 or 4. The earlier the stage, the more likely the surgery will remove all cancer.Oblast lioness. In Stage 3a, cancer is in the farthest layer of the uterus, tissue just outside this layer or tissue lining the abdominal wall. When cancer spreads to the vagina, it is a phase of 3b. Cancer in lymph nodes near the uterus is a phase of 3c.
The patient may undergo several different diagnostic tests before her doctor determines that she has a uterine cancer stage 3. The pelvic test is a typical screening test that doctors give to check abnormalities in the vagina and uterus. The physician can also use a hysteroscope or illuminated tube to explore the interior of the patient's uterus.
If uterine cancer is suspected, the diagnosis is confirmed by further testing. Transvaginal ultrasound creates a picture of a woman's uterus using sound waves that show the thickness, texture and any endometrial abnormalities. Surgically removing the sample of tissue from the -rhoha for testing is also a possible diagnostic test.
Treatment of uterine cancer Stadium 3 usually begins with radiation therapy and radical hysterectomy, which includes the removal of the lymph nodes of the pelvic and uterus, the cervix and part of the vagina. Patients who are not candidates for surgery may be subject to radiation and chemot itselferarapia. Hormonal therapy is perverted for those who cannot undergo radiation therapy or surgery.
The patient should be well informed about the production process, as an inaccurate performance can lead to ineffective treatment. The process should be a thorough and accurate phase determined as soon as the surgery is completed and all tissue samples have been analyzed. The average five -year survival rate in patients with uterine cancer is approximately 83 percent in all stages. This statistics are not determining because each case is unique; The patient's treatment team is the best source of questions about its forecast.